Viewing Expert Gordon Reid | StockChase
stockchase picture

Compiling comments that experts make about stocks while on public TV.

Viewing Expert

Gordon Reid , President

GoodReid Investment Counsel

Address
47 Colborne Street
Suite 400
Toronto, ON
M5E 1P8

Contact Info
Telephone: 416.364.0890
Toll Free: 1.888.466.3734
Fax: 416.364.1788
Email:


Date Signal Chart Symbol Company Opinion Price
2016-03-23 N/A Must be logged in to use chart A Commentary A Comment -- General Comments From an Expert

Markets. Volatility ironically gives him opportunities. When you are in a one-way market, it takes everything with it, the good and the bad. That makes it difficult for people who want to distinguish between good companies and bad companies. Stock picking, after been out of favour a few years, has come back and allowed people to do well if they choose carefully. His philosophy and process is to always take money off the table when companies become overextended. If a company does everything well, the market loves it and drives it up to a valuation level where it hasn’t been before, and that is the risk. In that case, you just take a piece off. As an example, he has held Apple (AAPL-Q) for 11 years, but he has trimmed it 7 times. He would have been better, from a rewards standpoint, to have held it throughout that time, but from a risk adjusted basis, he would not have.


Price:
$0.020
Subject:
US EQUITIES
Bias:
UNKNOWN
Owned:
_N/A
2016-03-23 COMMENT Must be logged in to use chart A Commentary A Comment -- General Comments From an Expert

Biotechs? A tough area. It has fundamental analysis, but also macro influences such as presidential elections, a lot of political commentary about drug prices, a Democratic presidential candidate who has a history of becoming involved in healthcare reform. A bit of a scary situation for potential investors. Have traded off to such an extent that some are quite attractive on a valuation basis and have some really fine growth characteristics. Biogen (BIIB-Q) and Celgene (CELG-Q) are good opportunities. He has stayed shy of the sector because of the macro influence of a potential democratic win.


Price:
$0.020
Subject:
US EQUITIES
Bias:
UNKNOWN
Owned:
Unknown
2016-03-23 COMMENT Must be logged in to use chart BA-N Boeing

Has owned this for some time. One of the nice things about ownership in this group is that the production process has evolved to the point where they are putting out the 787 Dreamliner and others, and doing quite well from both a revenue standpoint and a cash flow standpoint. These airplanes are much more fuel efficient.


Price:
$132.860
Subject:
US EQUITIES
Bias:
UNKNOWN
Owned:
Yes
2016-03-23 COMMENT Must be logged in to use chart BAC-N Bank of America

Citigroup (C-N) or Bank of America (BAC-N)? Trading at .6 to Tangible Book which is extremely low. It has been low for a while, but that doesn’t mean it can’t go lower. Everybody has been looking for a catalyst in this group. The consensus is that higher interest rates will do it. A 1% rise in interest rates will create billions of dollars of net income for these banks.


Price:
$13.620
Subject:
US EQUITIES
Bias:
UNKNOWN
Owned:
Unknown
2016-03-23 BUY on WEAKNESS Must be logged in to use chart BECN-Q Beacon Roofing Supply

2nd largest roofer in the US. A play on new homes, but also a play on the replacement market. 60% of US homes were built prior to 1990. This has had volatility over the years. Wait for an entry that is a little more attractive.


Price:
$40.430
Subject:
US EQUITIES
Bias:
UNKNOWN
Owned:
Yes
2016-03-23 COMMENT Must be logged in to use chart C-N CitiGroup

Citigroup (C-N) or Bank of America (BAC-N)? Trading at .6 to Tangible Book which is extremely low. It has been low for a while, but that doesn’t mean it can’t go lower. Everybody has been looking for a catalyst in this group. The consensus is that higher interest rates will do it. A 1% rise in interest rates will create billions of dollars of net income for these banks. He likes this bank’s leadership.


Price:
$42.370
Subject:
US EQUITIES
Bias:
UNKNOWN
Owned:
Yes
2016-03-23 PAST TOP PICK Must be logged in to use chart CVS-N CVS Health Corp

(A Top Pick March 30/15. Down 1.55%.) Has been relatively flat for the past year, but he really likes the space. There is a demographic tailwind. Also, the Affordable Care Act is bringing more people into the drugstore with insurance plans. They do over 1 billion prescriptions a year. Also, vertically integrated being a pharmacy benefits manager as well. Recently acquired Omnicare, a long term care provider. Thinks they will get about $6 a share in earnings, so it is not expensive. Still a Buy.


Price:
$100.740
Subject:
US EQUITIES
Bias:
UNKNOWN
Owned:
Yes
2016-03-23 COMMENT Must be logged in to use chart DIS-N Walt Disney

A great franchise, in a large part because of their film success with Star Wars. Have done well, but the stock market has punished them, mostly because of the cutting of the cord, cable packaging, and the risk it gives this company in the form of ESPN and ABC. About 45% of revenues come from these 2. There should be some worry on this, as they are losing subscribers. Trading close to 20X earnings. Sold his holdings a while back on those concerns and isn’t really interested in moving back in.


Price:
$96.830
Subject:
US EQUITIES
Bias:
UNKNOWN
Owned:
No
2016-03-23 PAST TOP PICK Must be logged in to use chart ESL-N Esterline Technologies

(A Top Pick March 30/15. Down 43.15%.) This is an example of a small-cap, $1.8 billion in market capitalization. They had a couple of issues. This is a provider of sensors, avionics and control systems to aircraft manufacturers, and that space got a little soft. On top of that they lost a bit of expense control and the earnings went flat. He likes it here on a rebound, which has already started.


Price:
$65.760
Subject:
US EQUITIES
Bias:
UNKNOWN
Owned:
Yes
2016-03-23 DON'T BUY Must be logged in to use chart GE-N General Electric

Owned this some years ago, but basically lost patience. In Jeff Immelt’s 15-year tenure, the revenue per share, the cash flow and the earnings have been flat. He would not be an owner of this.


Price:
$31.070
Subject:
US EQUITIES
Bias:
UNKNOWN
Owned:
No
2016-03-23 SELL Must be logged in to use chart GILD-Q Gilead Sciences Inc.

This has his own issues outside of any healthcare reforms. It is the leading producer of hepatitis C medication. They sell for exorbitant amounts, about $1000 a day for a 90-day course. Because it is a cure, this is a shrinking market. About 60% of this company’s total revenues are made up of just this drug group, which is dangerous in itself because of competition.


Price:
$90.080
Subject:
US EQUITIES
Bias:
UNKNOWN
Owned:
No
2016-03-23 COMMENT Must be logged in to use chart HON-N Honeywell International

Probably one of the best managed industrials there is in the US. It is about 40% in aerospace and 30%-35% in controls and sensors. Has done extremely well through this time of a strong US$. However, the dollar is not going to be a point of discussion in a month or 2.


Price:
$112.210
Subject:
US EQUITIES
Bias:
UNKNOWN
Owned:
No
2016-03-23 COMMENT Must be logged in to use chart MA-N Mastercard Inc.

Transaction driven and doesn’t take any credit risks. Both Visa (V-N) and this company are strong and consistent growers, and trade at a premium to the market. This is less debit card oriented and more credit card oriented. More domestic where Visa is more international. Prefers Visa which has metrics which he believes are somewhat better. (See Top Picks.)


Price:
$92.130
Subject:
US EQUITIES
Bias:
UNKNOWN
Owned:
Unknown
2016-03-23 TOP PICK Must be logged in to use chart PCLN-Q Priceline.com Inc.

He chose this because of what happened in Belgium in the last couple of days. This always trades off on these terrorists’ events. It is a fact that people will continue to travel, and this company will continue to do well. Trading at about 19X this year and about 18X next year. They have layered on internet options such as Booking.com, OpenTable for dinner reservations, Kayak for flights.


Price:
$1306.110
Subject:
US EQUITIES
Bias:
UNKNOWN
Owned:
Yes
2016-03-23 TOP PICK Must be logged in to use chart PRXL-Q Parexel International Corp.

A contract research organization that basically takes outsourced clinical studies on behalf of pharmaceuticals, runs the studies through various phases on behalf of them. They have $5.4 billion of backlog. Have just gone through a restructuring process which will be additive in the last half of this year to their earnings.


Price:
$59.400
Subject:
US EQUITIES
Bias:
UNKNOWN
Owned:
Yes
Showing 1 to 15 of 1,736 entries
<< < 1 2 3 4 5 > >>

No Comments.


You must be logged in to comment.